The Human Islet Research Network (HIRN) is announcing a competitive New Investigator Pilot Award. The goal of this award is to support a small number of new investigators of exceptional creativity who propose to apply bold and highly innovative new research approaches to biological problems under current investigation in HIRN. The HIRN New Investigator Pilot Award is designed to provide support for early career investigators who may need funding to explore feasibility of a new concept in support of an eventual R01 application. The research proposed must be relevant to the goals of HIRN consortia.

The key dates for the submission are summarized below. Application details are included in the attached PDF and on the HIRN website at: https://hirnetwork.org/newinvestigator2018

Key Dates:

Posted Date: November 15, 2017
Letter of Intent Due Date: December 15, 2017
Application Due Date: January 15, 2018
Scientific Review: February/March 2018
Start Date: June 1, 2018
Expiration Date: January 16, 2018

If you have any questions regarding the new investigator pilot award please contact the HIRN Coordinating Center (CC) at hirncc@coh.org.

Please share with your colleagues & peers!

From the:  HIRN Coordinating Center at City of Hope

Download

 

Dear Investigators,

JDRF is requesting applications for the following opportunity:

RESTORING PANCREATIC ALPHA CELL FUNCTION TO IMPROVE METABOLIC CONTROL IN TYPE 1 DIABETES

November 15, 2017 – LOI Launch
December 20, 2017 – LOI Deadline
January 17, 2018 – Full Proposal Notification
February 21, 2018 – Full Proposal Submission Deadline
August 2018 – Response to Applicants
October 2018 – Earliest Start Date


Please reference the RESTORING PANCREATIC ALPHA CELL FUNCTION TO IMPROVE METABOLIC CONTROL IN TYPE 1 DIABETES RFA for more information.

To apply, please submit your application via RMS360 
(https://jdrf.smartsimple.us).

Please feel free to share this opportunity with your colleagues. Additionally, please visit the Request for Applications section of the (http://grantcenter.jdrf.org/rfa/) regularly for more funding opportunities.

 

Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases

(RFA-DK-17-011)
Purpose: The Catalyst Award in Diabetes, Endocrinology and Metabolic Diseases (Catalyst-DEMD) is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and possibly transforming studies in DEMD topic areas. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases. To be considered responsive to this initiative, the proposed research must reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator's research program or elsewhere.   

Application due date: February 2, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement.

https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-17-011.html

 

Diabetic Foot Consortium - Clinical Research Units (UO1 funding opportunity)

Diabetic Foot Consortium - Clinical Research Units (U01)
(RFA-DK-17-014)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): January 23, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Purpose: This Funding Opportunity Announcement (FOA) invites applications for Clinical Research Units (CRUs) to form the new Diabetic Foot Consortium (DFC) for multi-site clinical research to validate biomarkers for diabetic foot ulcers that that can predict healing outcomes, guide treatment, and monitor healing and response to treatment.  The long-term goal is to lay the foundation for a clinical trial network to test therapies that can improve healing and prevent amputations.  

Funds Available:  The NIDDK intends to commit $1.5 million in FY 2018 to fund up to 10 awards.  In FY 2019 to FY 2021, the NIDDK intends to commit a total of $8.25 million with additional funding anticipated for specific research protocols.

Limited to ONE application

Eligibility: faculty with PI eligibility

The long-term goal is to lay the foundation for a clinical trial network to test therapies that can improve healing and prevent amputations. 

Internal submission guidelines:

By Tues., Oct. 31, 2017, 5 p.m., please submit one PDF file containing the following to Jeanne Heschele, Research Management Group (RMG) at jheschele@stanford.edu

1) Title Page

NIDDK Diabetic Foot Consortium - Clinical Research Units (U01) RFA-DK-17-014

Project Title

PI & Co-PI(s) name, title, department, phone and email address

2) Project summary-up to 4 pages (at least font size 11, single spaced)

3) PI & Co-PI Biosketches